Curetopia Raises $1.77M to Accelerate Rare Disease Cures Using DeSci
Curetopia, the first Biotech DAO (BioDAO) on Solana, has raised $1.77M to develop treatments in the $1T+ rare disease space. The raise comes on the heels of a recent discovery by Curetopia which could lead to the first-ever treatment for a disease developed by a DeSci project, with proceeds flowing back to the DAO.
Highlights:
- Curetopia, the first Biotech DAO (BioDAO) on Solana, has raised $1.77M from over 1,000 individual funders to develop treatments in the $1T+ rare disease space.
- The raise comes on the heels of a recent discovery by Curetopia which could lead to the first-ever treatment for a disease developed by a DeSci project, with potential proceeds flowing back to the DAO.
- In the past 3 months, DeSci has raised over $15 million in research funding, providing a lifeline to scientists amid ongoing NIH and NSF funding freezes.
Launched via the Bio Protocol launchpad, Curetopia is accelerating drug discovery for the 10,000+ rare diseases often overlooked by Big Pharma.
Curetopia's DAO enables rare disease patients and researchers to crowdfund using crypto and utilize the funding to develop treatments co-owned by the DAO. Patients who participate in Curetopia’s decentralized trials receive $CURES tokens, allowing participants to become stakeholders in medicines born from their data.
The raise comes on the heels of Curetopia’s recent discovery of a potential treatment for AARS2, a fatal rare disease with no approved treatments. Curetopia is in the process of filing a provisional patent based on the findings and tokenizing it, with proceeds flowing back to the DAO.
Curetopia is part of the emerging DeSci movement, which allows patient and researcher communities to interact directly on peer-to-peer networks. In the past 3 months, DeSci has raised over $15 million in research funding, providing a lifeline to scientists amid ongoing National Institute of Health (NIH) and National Science Foundation (NSF) funding freezes.
From Closed Laboratories to Open Science
Curetopia’s model isn’t limited to AARS2. The DAO’s decentralized, AI-driven approach can be applied across thousands of rare diseases, each with an average market size of $200-300M. In its initial phases, Curetopia will develop cures from repurposed, pre-approved drugs to bypass regulatory bottleknecks and accelerate treatment delivery.
